What is it about?
since the incidence of PC is associated with metabolic syndrome and Type 2 diabetes mellitus (T2DM), there is a need to uncouple these common metabolic dysregulations that may otherwise diminish the clinical utility of metabolomic biosignatures
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
Pancreatic cancer (PC) is an aggressive disease with high mortality rates, however, there is no blood test for early detection and diagnosis of this disease.
Perspectives
our study underscores the need for a more robust study design for cancer biomarker studies so as to maximize the translational value and clinical implementation.
Prof Nasser M Rizk
Mansoura University
Read the Original
This page is a summary of: Metabolomic biomarkers of pancreatic cancer: a meta-analysis study, Oncotarget, August 2017, Impact Journals, LLC,
DOI: 10.18632/oncotarget.20324.
You can read the full text:
Resources
Contributors
The following have contributed to this page
